Modulation of clinical drug resistance in a B cell lymphoma patient by the protein kinase inhibitor 7-hydroxystaurosporine: Presentation of a novel therapeutic paradigm

Clinical Cancer Research

Volumn 6, Issue 2, 2000, Pages 415-421

  Wilson, Wyndham H ^a   Sorbara, Lynn ^a   Figg, William D ^a   Mont, Erik K ^a   Sausville, Edward ^a   Warren, Katherine E ^a   Balis, Frank M ^a   Bauer, Ken ^a   Raffeld, Mark ^a   Senderowicz, Adrian M ^a   Monks, Anne ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYSTAUROSPORINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROTEIN KINASE INHIBITOR; VINCRISTINE;

AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; CASE REPORT; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LARGE CELL LYMPHOMA; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

AGED; ALKALOIDS; ANTINEOPLASTIC AGENTS; B-LYMPHOCYTES; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPH NODES; LYMPHOMA, B-CELL; MALE; NEOPLASM STAGING; PROTEIN KINASE C; STAUROSPORINE; T-LYMPHOCYTES; TISSUE DISTRIBUTION;

EID: 18844482122     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Wilson, W. H. Principles of chemotherapy. In: I. Magrath (ed.), The Non-Hodgkin's Lymphomas, Ed. 2, p. 631-648. London: Arnold, 1997.
2. Fisher, D. E. Apoptosis in cancer therapy: crossing the threshold. Cell, 78: 539-542, 1994.
3. Vaux, D. L., Haecker, G., and Strasser, A. An evolutionary perspective on apoptosis. Cell, 76: 777-779, 1994.
4. Sachs, L., and Lotem, J. Control of programmed cell death in normal and leukemic cells: new implications for therapy. Blood, 82: 15-21, 1993.
5. Wilson, W. H., Teruya-Feldstein, J., Fest, T., Harris, C., Steinberg, S. M., Jaffe, E. S., and Raffeld, M. Relationship of p53, bcl-2 and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood, 89: 601-609, 1997.
6. Senderowicz, A. M., Headlee, D., Lush, R., Arbuck, S., Bauer, K., Figg, W. D., Murgo, A., Inoue, K., Kobashi, S., Kuwabara, T., and Sausville, E. A. Phase I trial of infusional UCN-01, a novel protein kinase inhibitor in patients with refractory neoplasms. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 18: 612, 1999.
7. Bertrand, R., Solary, E., O'Connor, P., Kohn, K. W., and Pommier, Y. Induction of a common pathway of apoptosis by staurosporine. Exp. Cell Res., 211: 314-321, 1994.
8. Seynaeve, C., Kazanietz, M. G., Blumberg, P. M., Sausville, E. A., and Worland, P. J. Differential inhibition of protein kinase C isozymes by UCN-01: a staurosporine analogue. Mol. Pharmacol., 45: 1207-1304, 1994.
9. Akinaga, S., Gomi, K., Morimot, M., Tamaoki, T., and Okabe, M. Antitumor activity of UCN-01, a selective inhibitor of protein kinase C in murine and human tumor models. Cancer Res., 57: 4888-4893, 1991.
10. 2-checkpoint inhibitor. Clin. Cancer Res., 2: 791-797, 1996.
11. Shao, R. G., Cao, C. X., Shimizu, T., O'Connor, P. M., Kohn, K. W., and Pommier, Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res., 57: 4029-4035, 1997.
12. Akinaga, S., Nomura, K., Gomi, K., and Okabe, M. Enhancement of antitumor activity of mitomycin C in vitro and in vivo by UCN-01, a selective inhibitor of protein kinase C. Cancer Chemother. Pharmacol., 32: 183-189, 1993.
13. Monks, A., Harris, E., Connelly, J., and Hose, C. Enhancement of fludarabine and gemcitabine toxicity by UCN-01 in a variety of human tumor cell lines. Proc. Am. Assoc. Cancer Res., 40: 45, 1999.
14. Wang, Q., Worland, P. J., Clark, J. L., Carlson, B. A., and Sausville, E. A. Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2. Cell Growth Differ., 6: 927-933, 1995.
15. Wilson, W. H., Hakim, F., Little, R., Pearson, O., Statler-Stevenson, M. A., Steinberg, S. M., Jaffe, E. S., Witters, R., Elwood, P., and Gress, R. Phase II trial of high dose outpatient chemotherapy (EPOCH II) and interleukin-2 immunotherapy in lymphomas. Proc. Am. Soc. Clin. Oncol. Annu. Meet., 16: 84, 1997.
16. Wilson, W. H., Bryant, G., Bates, S., Fojo, A., Wittes, R. E., Steinberg, S. M., Kohler, D. R., Jaffe, E. S., Herdt, J., Cheson, B. D., and Chabner, B. A. EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J. Clin. Oncol., 11: 1573-1582, 1993.
17. Sambrook, J., Fritsch, E. F., and Maniatis, T. Molecular Cloning, Ed. 2. New York: Cold Spring Harbor Laboratory Press, 1989.
18. Segal, G. H., Jorgensen, T., Scott, M., and Braylan, R. C. Optimal primer selection for clonality assessment by polymerase chain reaction analysis. II. Follicular lymphomas. Hum. Pathol., 12: 1276-1283, 1994.
19. McCarthy, K., Sloane, J. P., Kabarowski, J. H. S., Matutes, E., and Wiedemann, L. M. A simplified method of detection of clonal rearrangements of the T-cell receptor-γ chain gene. Diagn. Mol. Pathol., 3: 173-178, 1992.
20. Strife, R. J., Jardine, I., and Colvin, M. Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography. J. Chromatogr. Biomed. Appl., 182: 211, 1980.
21. Jackson, D. V., Jr., Sethi, V. S., Spurr, C. L., White, D. R., Richards, F., Stuart, J. J., Muss, H. B., Cooper, M. R., and Castle, M. C. Pharmacokinetics of vincristine infusion. Cancer Treat. Rep., 65: 11-18, 1981.
22. Wilson, W. H., Jamis-Dow, C., Bryant, G., Balis, F. M., Klecker, R. W., Bates, S. E., Chabner, B. A., Steinberg, S. M., Kohler, D. R., and Wittes, R. E. Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapy. J. Clin. Oncol., 13: 1985-1994, 1995.
23. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jack, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
24. Fujiwara, T., Grimm, E. A., Mukhopadhyay, T., Zhang, W. W., Owen-Schaub, L. B., and Roth, J. A. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res., 54: 2287-2293, 1994.
25. Walton, M. I., Whysong, D., O'Connor, P. M., Hockenbery, D., Korsmeyer, S. J., and Kohn, K. W. Constitutive expression of human bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res., 55: 1853-1861, 1993.
26. Seynaeve, C. M., Stetler-Stevenson, M., Sebers, S., Kaur, G., Sausville, E. A., and Worland, P. J. Cell cycle arrest and growth inhibition by the protein kinase antagonist UCN-01 in human breast carcinoma cells. Cancer Res., 53: 2081-2086, 1993.
27. Takahashi, I., Saitoh, Y., Yoshida, M., Sano, H., Nakano, H., Morimoto, M., and Tamaoki, T. UCN-01 and UCN-02, new selective inhibitors of protein kinase C. II. Purification, physico-chemical properties, structural determination and biological activities. J. Antibiot. (Japan), 42: 571-576, 1989.
28. Tamaoki, T., and Nakano, H. Potent and specific inhibitors of protein kinase C of microbial origin. Biotechnology (NY), 8: 732, 1990.
29. 2 checkpoint function in cancer cells with disrupted p53. J. Natl. Cancer Inst., 88: 956-965, 1996.
30. 2 arrest through a cdk2-dependent pathway that involves inactivation of the Wee1Hu kinase. J. Biol. Chem., 275: 33455-33464, 1998.
31. 1 phase of the cell cycle. Cancer Res., 57: 2379-2385, 1991.
32. Houghton, J. A., Harwood, F. G., and Houghton, P. J. Cell cycle control processes determine cytostasis or cytotoxicity in thymineless death of colon cancer cells. Cancer Res., 54: 4967-4973, 1994.
33. Shan, D. S., Ledbetter, J. A., and Press, O. W. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood, 91: 1644-1652, 1998.